3 results
Approved WMOCompleted
Primary ObjectivesTo assess the safety of 2 fixed doses of EVP-6124 (2 or 3 mg daily) for up to 52 weeks in subjects withAlzheimer*s disease (AD) who complete (Day 182) studies EVP-6124-024 or EVP-6124-025Secondary ObjectivesTo assess the duration…
Approved WMOCompleted
In this research we want to determine whether patients prefer the ProTrach DualCare over other speaking valves, if it improves quality of life, compliance with HME use and lung function.
Approved WMORecruiting
The purpose of this scientific study is to verify whether immunotherapy (L19-IL2) after a standard treatment such as radiotherapy, fights the metastatic disease more efficiently than the current standard treatment alone.